Skip to main content

Table 4 Severity of adverse effects of chemotherapy regimens

From: Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients

ADR

Chemotherapy regimens

P-Value*

 

FOLOFOX

FOLFIRI

Capecitabine + Cetuximab

Capecitabine

FOLOFOX + Irinotecan

5-FU

Total

Diarrhea

Grade 1

14 (35.9%)

4 (28.6%)

0 (0%)

1 (100%)

2 (100%)

0 (0%)

21 (37.5%)

0.96

Grade 2

12 (30.8%)

5 (35.7%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

17 (30.4%)

Grade 3

7 (17.9%)

3 (21.4%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

10 (17.9%)

Grade 4

6 (15.4%)

2 (14.3%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

8 (14.3%)

Nausea

Grade 1

33 (68.8%)

7 (50%)

1 (50%)

2 (100%)

2 (66.7%)

0 (0%)

45 (64.3%)

0.32

Grade 2

14 (29.2%)

7 (50%)

1 (50%)

0 (0%)

1 (33.3%)

1 (100%)

24 (34.3%)

Grade 3

1 (2.1%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

1 (1.4%)

Vomiting

Grade 1

17 (6.7%)

5 (55.6%)

1 (100%)

2 (100%)

1 (33.3%)

1 (100%)

27 (61.4%)

0.91

Grade 2

7 (25%)

3 (33.3%)

0 (0%)

0 (0%)

2 (66.7%)

0 (0%)

12 (27.3%)

Grade 3

3 (10.7%)

1 (11.1%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

4 (9.1%)

Grade 4

1 (3.6%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

1 (2.3%)

Oral mucositis

Grade 1

24 (61.4%)

11 (61.1%)

0 (0%)

0 (0%)

1 (50%)

0 (0%)

36 (46.2%)

Grade 2

19 (27.3%)

4 (22.2%)

0 (0%)

2 (100%)

1 (50%)

1 (100%)

27 (34.6%)

0.59

Grade 3

11 (9.1%)

3 (16.7%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

14 (17.9%)

Grade 4

1 (2.3%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

1 (1.3%)

Peripheral neuropathy

Grade 1

89 (56%)

16 (44.4%)

0 (0%)

2 (40%)

4 (80%)

0 (0%)

111 (53.1%)

0.39

Grade 2

69 (43.4%)

20 (55.6%)

3 (100%)

2 (40%)

1 (20%)

1 (100%)

96 (45.9%)

Grade 3

1 (0.6%)

0 (0%)

0 (0%)

1 (20%)

0 (0%)

0 (0%)

2 (1%)

Hair loss

Grade 1

53 (94.6%)

19 (79.2%)

2 (100%)

5 (100%)

1 (33.3%)

0 (0%)

80 (87.9%)

0.03

Grade 2

3 (5.4%)

5 (20.8%)

0 (0%)

0 (0%)

2 (66.7%)

1 (100%)

11 (12.1%)

  1. ADR adverse drug reaction, 5-FU 5-Fluorouracil, FOLFOX 5-FU / leucovorin and oxaliplatin, FOLFIRI 5-FU / leucovorin and irinotecan; *: P-value represents the difference between FOLFOX and FOLFIRI regimens